170 related articles for article (PubMed ID: 38112840)
1. Dual-Targeted Therapy with Upadacitinib and Ustekinumab in Medically Complex Crohn's Disease.
Miyatani Y; Choi D; Choi NK; Rubin DT
Dig Dis Sci; 2024 Feb; 69(2):355-359. PubMed ID: 38112840
[TBL] [Abstract][Full Text] [Related]
2. Ustekinumab for Crohn's disease: a nationwide real-life cohort study from Finland (FINUSTE).
Eberl A; Hallinen T; Af Björkesten CG; Heikkinen M; Hirsi E; Kellokumpu M; Koskinen I; Moilanen V; Nielsen C; Nuutinen H; Suhonen UM; Utriainen K; Vihriälä I; Soini E; Wennerström C; Nissinen R; Borsi A; Koivunen M; Tillonen J; Sipponen T
Scand J Gastroenterol; 2019 Jun; 54(6):718-725. PubMed ID: 31184512
[No Abstract] [Full Text] [Related]
3. The impact of ustekinumab on extraintestinal manifestations of Crohn's disease: A post hoc analysis of the UNITI studies.
Narula N; Aruljothy A; Wong ECL; Homenauth R; Alshahrani AA; Marshall JK; Reinisch W
United European Gastroenterol J; 2021 Jun; 9(5):581-589. PubMed ID: 34077627
[TBL] [Abstract][Full Text] [Related]
4. Matching-Adjusted Indirect Comparison Between Risankizumab and Ustekinumab for Induction and Maintenance Treatment of Moderately to Severely Active Crohn's Disease.
Dubinsky M; Ma C; Griffith J; Crowell M; Neimark E; Kligys K; O'Connell T
Adv Ther; 2023 Sep; 40(9):3896-3911. PubMed ID: 37368103
[TBL] [Abstract][Full Text] [Related]
5. [Analysis on the efficacy of dual vein induction therapy of Ustekinumab in complex perianal fistulizing Crohn's disease].
Zhang DL; Shao XX; Hu DY; Lin DP; Wu H; Jiang Y
Zhonghua Yi Xue Za Zhi; 2023 Nov; 103(41):3301-3306. PubMed ID: 37926575
[No Abstract] [Full Text] [Related]
6. Ustekinumab in Crohn's disease: effectiveness and safety in clinical practice.
Saldaña Dueñas C; Rullán Iriarte M; Elosua González A; Rodríguez Gutiérrez C; Rubio Iturria S; Nantes Castillejo Ó
Gastroenterol Hepatol; 2020 Nov; 43(9):497-505. PubMed ID: 32703654
[TBL] [Abstract][Full Text] [Related]
7. Long-term effectiveness and safety of ustekinumab in bio-naïve and bio-experienced anti-tumor necrosis factor patients with Crohn's disease: a real-world multicenter Brazilian study.
Parra RS; Chebli JMF; Queiroz NSF; Damião AOMC; de Azevedo MFC; Chebli LA; Bertges ER; Alves Junior AJT; Ambrogini Junior O; da Silva BLPS; Lubini M; Bafutto M; Flores C; Vilela EG; Boratto SF; Gasparetti Junior NLT; Steinwurz F; Carvalho NS; Féres O; da Rocha JJR
BMC Gastroenterol; 2022 Apr; 22(1):199. PubMed ID: 35448949
[TBL] [Abstract][Full Text] [Related]
8. [Clinical remission and transmural healing of ustekinumab in patients with Crohn's disease].
Wu Y; Xu Y; Zhang G; Zhang Y; Wang J; You P; Peng T; Liu Y; Chen N
Beijing Da Xue Xue Bao Yi Xue Ban; 2024 Apr; 56(2):253-259. PubMed ID: 38595241
[TBL] [Abstract][Full Text] [Related]
9. Inflammatory Cutaneous Lesions in Inflammatory Bowel Disease Treated With Vedolizumab or Ustekinumab: An ECCO CONFER Multicentre Case Series.
Phillips FM; Verstockt B; Sebastian S; Ribaldone D; Vavricka S; Katsanos K; Slattery E; de Suray N; Flores C; Fries W; Vincenzi F; Capoferro E; Bachmann O; Kopylov U
J Crohns Colitis; 2020 Oct; 14(10):1488-1493. PubMed ID: 32318735
[TBL] [Abstract][Full Text] [Related]
10. Real-World Effectiveness and Safety of Ustekinumab in Elderly Crohn's Disease Patients.
Garg R; Aggarwal M; Butler R; Achkar JP; Lashner B; Philpott J; Cohen B; Qazi T; Rieder F; Regueiro M; Click B
Dig Dis Sci; 2022 Jul; 67(7):3138-3147. PubMed ID: 34160735
[TBL] [Abstract][Full Text] [Related]
11. Adalimumab versus ustekinumab as first-line biological in moderate-to-severe Crohn's disease: real-life cohort from a tertiary referral center.
Moens A; Alsoud D; Verstockt B; Sabino J; Ferrante M; Vermeire S
Eur J Gastroenterol Hepatol; 2022 Oct; 34(10):1015-1020. PubMed ID: 36062494
[TBL] [Abstract][Full Text] [Related]
12. Ustekinumab trough concentration affects clinical and endoscopic outcomes in patients with refractory Crohn's disease: a Chinese real-world study.
Yao JY; Zhang M; Wang W; Peng X; Zhao JZ; Liu T; Li ZW; Sun HT; Hu P; Zhi M
BMC Gastroenterol; 2021 Oct; 21(1):380. PubMed ID: 34663208
[TBL] [Abstract][Full Text] [Related]
13. Real-world Comparative Effectiveness of Ustekinumab vs Anti-TNF in Crohn's Disease With Propensity Score Adjustment: Induction Phase Results From the Prospective, Observational RUN-CD Study.
Bokemeyer B; Plachta-Danielzik S; di Giuseppe R; Mohl W; Teich N; Hoffstadt M; Schweitzer A; von der Ohe M; Gauss A; Atreya R; Krause T; Blumenstein I; Hartmann P; Schreiber S
Inflamm Bowel Dis; 2023 Nov; 29(11):1741-1750. PubMed ID: 36633301
[TBL] [Abstract][Full Text] [Related]
14. Safety and effectiveness of ustekinumab for induction of remission in patients with Crohn's disease: A multicenter Israeli study.
Bar-Gil Shitrit A; Ben-Ya'acov A; Siterman M; Waterman M; Hirsh A; Schwartz D; Zittan E; Adler Y; Koslowsky B; Avni-Biron I; Chowers Y; Ron Y; Israeli E; Ungar B; Yanai H; Maharshak N; Ben-Horin S; Eliakim R; Dotan I; Goldin E; Kopylov U
United European Gastroenterol J; 2020 May; 8(4):418-424. PubMed ID: 32213026
[TBL] [Abstract][Full Text] [Related]
15. Clinical, endoscopic and radiographic outcomes with ustekinumab in medically-refractory Crohn's disease: real world experience from a multicentre cohort.
Ma C; Fedorak RN; Kaplan GG; Dieleman LA; Devlin SM; Stern N; Kroeker KI; Seow CH; Leung Y; Novak KL; Halloran BP; Huang VW; Wong K; Blustein PK; Ghosh S; Panaccione R
Aliment Pharmacol Ther; 2017 May; 45(9):1232-1243. PubMed ID: 28252210
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of ustekinumab trough levels during induction and maintenance therapy with regard to disease activity status in difficult to treat Crohn disease patients.
Mechie NC; Burmester M; Mavropoulou E; Pilavakis Y; Kunsch S; Ellenrieder V; Amanzada A
Medicine (Baltimore); 2021 Mar; 100(11):e25111. PubMed ID: 33725990
[TBL] [Abstract][Full Text] [Related]
17. Real-world effectiveness and safety of ustekinumab and vedolizumab in elderly patients with Crohn's disease.
Garg R; Aggarwal M; Mohammed A; Achkar JP; Lashner B; Philpott J; Cohen B; Qazi T; Rieder F; Regueiro M; Click B
Indian J Gastroenterol; 2023 Oct; 42(5):718-723. PubMed ID: 37523059
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of swapping to ustekinumab after vedolizumab failure in patients with multi-refractory Crohn's disease.
Melotti L; Dussias NK; Salice M; Calabrese C; Baldoni M; Scaioli E; Belluzzi A; Mazzotta E; Gionchetti P; Rizzello F
Dig Liver Dis; 2023 Feb; 55(2):230-234. PubMed ID: 35879185
[TBL] [Abstract][Full Text] [Related]
19. The Real-World Effectiveness and Safety of Ustekinumab in the Treatment of Crohn's Disease: Results From the SUCCESS Consortium.
Johnson AM; Barsky M; Ahmed W; Zullow S; Galati J; Jairath V; Narula N; Peerani F; Click BH; Coburn ES; Dang TT; Gold S; Agrawal M; Garg R; Aggarwal M; Mohammad D; Halloran B; Kochhar GS; Todorowski H; Ud Din NM; Izanec J; Teeple A; Gasink C; Muser E; Ding Z; Swaminath A; Lakhani K; Hogan D; Datta S; Ungaro RC; Boland BS; Bohm M; Fischer M; Sagi S; Afzali A; Ullman T; Lawlor G; Baumgart DC; Chang S; Hudesman D; Lukin D; Scherl EJ; Colombel JF; Sands BE; Siegel CA; Regueiro M; Sandborn WJ; Bruining D; Kane S; Loftus EV; Dulai PS
Am J Gastroenterol; 2023 Feb; 118(2):317-328. PubMed ID: 36191274
[TBL] [Abstract][Full Text] [Related]
20. The effectiveness of ustekinumab and vedolizumab as third-line biologic therapy in patients with Crohn's disease.
Macaluso FS; Grova M; Saladino M; Cappello M; Demarzo MG; Privitera AC; Giangreco E; Garufi S; Renna S; Casà A; Ventimiglia M; Fries W; Orlando A;
Dig Liver Dis; 2023 Apr; 55(4):471-477. PubMed ID: 36127230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]